Perjeta 420 mg concentrate for solution for infusion, PERTUZUMAB clinical trials

A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer

This study looks at a new way to treat early breast cancer that is HER2-positive. It compares a combination of medicines (trastuzumab, pertuzumab, and docetaxel) to the usual treatment to see which is better at preventing the cancer from coming back.